Carter Sophie, Li Zhuo, Lemieux Isabelle, Alméras Natalie, Tremblay Angelo, Bergeron Jean, Poirier Paul, Deshaies Yves, Després Jean-Pierre, Picard Frédéric
Centre de recherche de l'Institut universitaire de cardiologie et de pneumologie de Québec, Québec, QC, Canada; Faculty of Pharmacy, Université Laval, Québec, QC, Canada.
Centre de recherche de l'Institut universitaire de cardiologie et de pneumologie de Québec, Québec, QC, Canada.
Atherosclerosis. 2014 Dec;237(2):645-51. doi: 10.1016/j.atherosclerosis.2014.09.022. Epub 2014 Oct 2.
To assess whether plasma IGFBP-2 is independently associated with components of the lipoprotein-lipid profile and to suggest a cutoff value that could identify subjects with the features of the metabolic syndrome.
In this cross-sectional study, 379 Caucasian men from the general population and covering a wide range of BMI were recruited through the media. Subjects with type 2 diabetes, BMI values > 40 kg/m(2), or taking medication targeting glucose or lipid metabolism or blood pressure were excluded. Anthropometric data were collected and plasma IGFBP-2 concentrations, glucose tolerance and an extensive plasma lipid profile were determined after an overnight fast.
Subjects with low IGFBP-2 levels were characterized by increased fat mass (p < 0.0001), impaired insulin sensitivity (p < 0.0001) and higher plasma triglyceride (TG) levels (p < 0.0001). When divided into 6 quantiles, only subjects with the highest IGFBP-2 levels (>221.5 ng/mL) did not meet the NCEP ATP III criteria for the clinical diagnosis of the metabolic syndrome. In addition, circulating IGFBP-2 levels were significantly associated with VLDL-TG (r = -0.51, p < 0.0001) and HDL-C (r = -0.27, p < 0.0001) levels. After adjustments, plasma IGFBP-2 was found to be independently associated with VLDL-TG levels but not with HDL-C concentrations.
In our cohort, IGFBP-2 levels <221.5 ng/mL are incrementally associated with a detrimental plasma lipoprotein-lipid profile. After adjustment for covariates, IGFBP-2 remained independently associated with VLDL-TG but not HDL-C levels. This study supports further investigations in other populations and validation of IGFBP-2 as a biomarker of early dyslipidemia.
评估血浆胰岛素样生长因子结合蛋白-2（IGFBP-2）是否与脂蛋白-脂质谱的各组分独立相关，并提出一个能够识别具有代谢综合征特征受试者的临界值。
在这项横断面研究中，通过媒体招募了379名来自普通人群、BMI范围广泛的白人男性。排除患有2型糖尿病、BMI值>40kg/m²或正在服用针对糖代谢、脂代谢或血压的药物的受试者。收集人体测量数据，并在禁食过夜后测定血浆IGFBP-2浓度、葡萄糖耐量和广泛的血浆脂质谱。
IGFBP-2水平低的受试者具有脂肪量增加（p<0.0001）、胰岛素敏感性受损（p<0.0001）和血浆甘油三酯（TG）水平较高（p<0.0001）的特征。当分为6个分位数时，只有IGFBP-2水平最高（>221.5ng/mL）的受试者不符合美国国家胆固醇教育计划成人治疗组第三次报告（NCEP ATP III）代谢综合征临床诊断标准。此外，循环IGFBP-2水平与极低密度脂蛋白甘油三酯（VLDL-TG）（r=-0.51，p<0.0001）和高密度脂蛋白胆固醇（HDL-C）（r=-0.27，p<0.0001）水平显著相关。调整后发现，血浆IGFBP-2与VLDL-TG水平独立相关，但与HDL-C浓度无关。
在我们的队列中，IGFBP-2水平<221.5ng/mL与有害的血浆脂蛋白-脂质谱逐渐相关。调整协变量后，IGFBP-2仍与VLDL-TG独立相关，但与HDL-C水平无关。本研究支持在其他人群中进行进一步研究，并验证IGFBP-2作为早期血脂异常生物标志物的有效性。
